# Experimental Tumor Model Shared Resource

> **NIH NIH P30** · ROSWELL PARK CANCER INSTITUTE CORP · 2021 · $83,379

## Abstract

As a result of CCSG strategic planning and evaluation of services offered, the former Mouse Tumor Models
shared resource (MTM) was renamed the Experimental Tumor Model Shared Resource (ETM). ETM has
expanded its experimental models to include xenografts, organoid and spheroid models from patient derived
samples. The major objective is to provide high quality, cost-effective, custom services tailored to the needs of
individual investigators and to provide a consolidated resource of experimental models and technical expertise
for all aspects of in vivo experiments to support the research efforts of CCSG investigators. The ETM shared
resource served a total of 65 Roswell users, of which 60 (92%) were CCSG members. ETM is a great value for
their users as there are no commercial options that offer the full range of services for in vivo studies that are
provided by ETM. The consolidated breeding colonies for the production of animals offer a profound savings
over buying the transgenic mice through commercial sources. The ETM resource has two primary areas of
focus: (i) experimental studies that utilize cancer models which includes maintaining models; biobank of tissues
from each model; and providing technical support for treatment, evaluation of response and tissue
procurement; and (ii) histological services for murine tissues. ETM service includes the full spectrum starting
with study protocol development, providing experimental models, performing in vivo treatments to tissue
procurement and histological staining with standardize murine IHC protocols. The histology services offered by
ETM are focused on murine tissues. The resource maintains breeding colonies of several widely used models
of prostate cancer. The ETM also maintains transgenic-based models of sarcoma, lung, pancreas (in
development), and a carcinogen-induced model of bladder cancer. The ETM establishes and maintains a
variety of patient-derived xenograft (PDX) models. The Specific Aims of the ETM are: 1) To provide a
consolidated resource for conducting in vivo studies utilizing experimental models of cancer including
biospecimens, experimental models and technical support for in vivo studies, and 2) To provide tissue
procurement and histological support for research involving experimental models. ETM plans to establish new
PDX models from clinical samples; establish lung squamous carcinomas PDXs with deep molecular
characterization; establish PDXs, organoids and spheroids from the same patient samples; provide multiple
transgenic models, PDX and 3-D culture methods; and establish the KPC transgenic model, biorepository of
pancreatic models and tissues, and patient derived models (xenograft, organoids and spheroids).

## Key facts

- **NIH application ID:** 10148651
- **Project number:** 5P30CA016056-44
- **Recipient organization:** ROSWELL PARK CANCER INSTITUTE CORP
- **Principal Investigator:** Barbara A. Foster
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $83,379
- **Award type:** 5
- **Project period:** 1997-06-16 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10148651

## Citation

> US National Institutes of Health, RePORTER application 10148651, Experimental Tumor Model Shared Resource (5P30CA016056-44). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10148651. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*